Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy
International Journal of Nanomedicine · 2025
DOI: 10.2147/ijn.s507688 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Hong-Kook Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: AI-Super Convergence KIURI Translational Research Center, Ajou University, Suwon, 16499, Republic of Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, CRISPR-Cas Systems, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AI-Super Convergence KIURI Translational Research Center, Ajou University, Suwon, 16499, Republic of Korea.
- Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, 16499, Republic of Korea.
- Department of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea.
ORCID-Profile: Hong-Kook Kim, Heedon Cheong, Hyo-Eon Jin
Zitieren
APA
Kim, H. K., Cheong, H., Kim, M. Y., & Jin, H. E. (2025). Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s507688
Vancouver
Kim HK, Cheong H, Kim MY, Jin HE. Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s507688
BibTeX
@article{Kim2025,
author = {Kim, Hong-Kook and Cheong, Heedon and Kim, Moo-Yeon and Jin, Hyo-Eon},
title = {Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy},
journal = {International Journal of Nanomedicine},
year = {2025},
doi = {10.2147/ijn.s507688}
}
EUVIMED